Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.65.
Forward PE Ratio (14.65) = Close Price ($52.41) / Consensus Forward EPS ($3.58)
FORWARD PE RATIO
14.65
SECTOR MEDIAN · HEALTHCARE
19.91
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-26.44%
vs the sector median at left
GSK plc
Market Cap
$105.00B
Forward PE Ratio
14.65
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GSK plc (GSK) | $105.00B | 14.65 |
| McKesson Corporation (MCK)vs › | $100.56B | 22.02 |
| HCA Healthcare, Inc. (HCA)vs › | $92.92B | 14.54 |
| CVS Health Corp. (CVS)vs › | $118.69B | 11.66 |
| Medtronic plc (MDT)vs › | $119.49B | 16.92 |
| Elevance Health Inc. (ELV)vs › | $86.86B | 14.75 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $85.92B | 15.38 |
| Stryker Corporation (SYK)vs › | $126.30B | 21.93 |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.83B | 35.08 |
| Boston Scientific Corporation (BSX)vs › | $74.87B | 15.25 |
Trailing P/E
16.6
reported TTM EPS
Forward P/E
14.7
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.58 implies +13.3% EPS growth vs the reported trailing $3.16.
At today's $52.41 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.58 | $3.52 – $3.67 | 6 | 14.6x |
| 2027-12-31 | $3.84 | $3.65 – $4.07 | 6 | 13.6x |
| 2028-12-31 | $4.07 | $3.75 – $4.56 | 10 | 12.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute